FDA Rejects Rare Disease Treatment Despite Strong Clinical Data: Biohaven Challenges Regulatory Decision on Spinocerebellar Ataxia Drug
Biohaven Pharmaceuticals faced a significant setback when the U.S. Food and Drug Administration issued a Complete Response Letter (CRL) rejecting the company's New Drug Application for Vyglxia (troriluzole), a promising…
Continue Reading
FDA Rejects Rare Disease Treatment Despite Strong Clinical Data: Biohaven Challenges Regulatory Decision on Spinocerebellar Ataxia Drug
